HOPE - Hope Bancorp, Inc.
Hope Bancorp is rated Buy, trading below book value and at a 43% discount to the financial sector despite a forward ROE 5.6x higher than the sector median. The MANUBANK acquisition is expected to drive near-term earnings growth, with management guiding for 20% loan and 15–20% revenue growth in FY26. NIM expansion, robust CET1 ratio (12.3%), and stable asset quality support a 4.2% yield and ongoing share repurchases.
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (“the Company”) (NASDAQ: HOPE) today announced that the Company will report financial results for its third quarter and nine months ended September 30, 2026, before the markets open on Wednesday, October 28, 2026. A conference call to discuss financial results for the third quarter and nine months ended September 30, 2026, will be held on Wednesday, October 28, 2026, at 9:30 a.m. Pacific Time / 12:30 p.m. Eastern Time. A presentation deck to acco.
Hope Bancorp (HOPE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Hope Bancorp, Inc. (NASDAQ: HOPE - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $13.06 and traded as high as $13.75. Hope Bancorp shares last traded at $13.57, with a volume of 1,048,202 shares traded. Wall Street Analyst Weigh In Several
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD).
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (NASDAQ: HOPE) today announced that its wholly-owned subsidiary, Bank of Hope (“the Bank”), has completed its previously announced acquisition of the Commercial Banking Unit of SMBC MANUBANK (“MANUBANK”), a wholly-owned subsidiary of SMBC Americas Holdings, Inc. and Sumitomo Mitsui Banking Corporation (“SMBC”). The acquisition adds an established commercial banking franchise and seasoned professionals to Bank of Hope, diversifying its deposit seg.
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company's lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a late-breaking poster and an oral presentation at the 31 st Annual Congress of the World Muscle Society (WMS 2026), taking place September 29 – October 3, 2026, in Hiroshima, Japan.
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (NASDAQ: HOPE) today announced that its wholly-owned subsidiary, Bank of Hope, has received all regulatory approvals required to complete the previously announced acquisition of the Commercial Banking Unit of SMBC MANUBANK (“MANUBANK”), a wholly owned subsidiary of SMBC Americas Holdings, Inc. and Sumitomo Mitsui Banking Corporation (“SMBC”). Regulatory approvals have been received from the Federal Deposit Insurance Corporation and the California.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi
--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit--
Hope Bancorp delivered a strong Q2 2026, with revenue and adjusted EPS both exceeding analyst expectations and a swing from loss to profit. HOPE's net interest margin expanded to 2.96%, deposits and loans grew, and non-interest income rebounded sharply due to the absence of prior-year securities losses. Despite trading below book value, HOPE's forward P/E of 13.8 and subpar asset quality (ROA 0.71%, ROE 5.76%) limit its attractiveness.
NEW YORK--(BUSINESS WIRE)--Bank of Hope, subsidiary of Hope Bancorp, Inc. (NASDAQ: HOPE), is expanding the ways it connects with customers and community members through a creative branding campaign centered on a sponsorship of 'BTS THE CITY ARIRANG NEW YORK'. Celebrating ‘BTS THE CITY ARIRANG NEW YORK' as people from around the world gather in New York City, this campaign serves as a unique activation targeted at today's consumers who seek meaningful relationships with the brands with which the.
Hope Bancorp, Inc. (HOPE) Q2 2026 Earnings Call Transcript
Hope Bancorp NASDAQ: HOPE reported higher second-quarter earnings and revenue as net interest margin expanded, loan growth accelerated and the company continued to improve its deposit mix ahead of its planned acquisition of SMBC MANUBANK's commercial banking unit.
While the top- and bottom-line numbers for Hope Bancorp (HOPE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hope Bancorp (HOPE) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.19 per share a year ago.
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (the “Company”) (NASDAQ: HOPE), the holding company of Bank of Hope (the “Bank”), today reported unaudited financial results for its second quarter and six months ended June 30, 2026. For the second quarter of 2026, the Company reported net income of $33.0 million, or $0.26 per diluted common share, up 12% from net income of $29.5 million, or $0.23 per diluted common share, for the first quarter of 2026, and up from a net loss of $24.8 million, o.
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (the “Company”) (NASDAQ: HOPE) today announced that its Board of Directors declared a quarterly cash dividend of $0.14 per common share. The dividend is payable on or about August 20, 2026, to all stockholders of record as of the close of business on August 6, 2026.About Hope Bancorp, Inc.Hope Bancorp, Inc. (NASDAQ: HOPE) is the holding company for Bank of Hope, with $18.99 billion in total assets as of June 30, 2026. Following the addition of Ter.
Fifth Third Bancorp raised its position in shares of Hope Bancorp, Inc. (NASDAQ: HOPE) by 9,776.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,303 shares of the financial services provider's stock after buying an additional 141,852 shares during the
NEW YORK--(BUSINESS WIRE)--Bank of Hope is turning up the volume on community engagement with a unique activation designed to celebrate and create meaningful and memorable experiences as part of their sponsorship of 'BTS THE CITY ARIRANG NEW YORK' in New York City.